IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients
The results of this study suggest that the expression of IL13Rα2 might be used as a potential prognostic indicator in osteosarcoma patients. Furthermore, it is observed that IL13Rα2 influences the resistance to the chemotherapeutic agent doxorubicin. Therefore, a therapeutic trial targeting IL13Rα2 might be a new therapeutic strategy for osteosarcoma, especially those highly expressing IL13Rα2.
Authors
- Ho Sung Park (ORCID: https://orcid.org/0000-0002-4879-874X)
- Kyoung Min Kim (ORCID: https://orcid.org/0000-0001-5703-4824)
- See‐Hyoung Park (ORCID: https://orcid.org/0000-0003-0020-7389)
- Maryam Karamikheirabad (ORCID: https://orcid.org/0000-0002-6819-7511)
- Kyu Yun Jang (ORCID: https://orcid.org/0000-0002-5276-4446)
- Ae-Ri Ahn
- Young Jae Moon (ORCID: https://orcid.org/0000-0002-5285-7618)
- Junyue Zhang (ORCID: https://orcid.org/0000-0003-1041-6133)
Institutions
- Jeonbuk National University Hospital (KR)
- Jeonbuk National University (KR)
- Hongik University (KR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-11-13
- DOI
- https://doi.org/10.3390/ph17111526
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Korea Institute of Radiological and Medical Sciences